Literature DB >> 18635700

Risk of cerebrovascular events in elderly users of antipsychotics.

B C Kleijer1, R J van Marum, A C G Egberts, P A F Jansen, W Knol, E R Heerdink.   

Abstract

It has been shown that elderly patients with dementia treated with atypical and conventional antipsychotics have a twofold increased risk of cerebrovascular adverse events (CVAEs). To investigate the temporal relationship between exposure to antipsychotics and the risk of CVAE, a case-control analysis nested within a cohort of 26,157 community-dwelling patients (mean age 76 +/- 9.7) with at least one antipsychotic prescription was conducted. Data were used from Dutch community pharmacies and hospital discharge records. Five hundred and eighteen cases of hospital admission for CVAE were identified. For each case, four randomly selected controls matched by sex and age were sampled from the cohort. To evaluate the temporal relationship between antipsychotic use and the occurrence of CVAE, two measures were used: the first being a current, recent or past user, and the second for the current users, the duration of use up to the index date. In addition, the cumulative exposure was assessed. Current and recent exposure to antipsychotics were associated with an increased risk of CVAE compared with non-users (odds ratio [OR] 1.7, CI 1.4-2.2). A strong temporal relationship was found; the OR for a history of use less than a week is 9.9 (5.7-17.2). The risk decreases in time and is comparable to non-users after 3 months of use (OR 1.0, CI 0.7-1.3). Cumulative exposure was not associated with an increase in risk. The risk of CVAE in elderly patients associated with antipsychotics is elevated especially during the first weeks of treatment. This risk decreases over time and is back on base level after 3 months of treatment. Chronic use is not associated with CVAE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18635700     DOI: 10.1177/0269881108093583

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  31 in total

Review 1.  Off-label prescribing in older patients.

Authors:  Stephen H D Jackson; Paul A F Jansen; Arduino A Mangoni
Journal:  Drugs Aging       Date:  2012-06-01       Impact factor: 3.923

2.  Risk of hospitalization for stroke associated with antipsychotic use in the elderly: a self-controlled case series.

Authors:  Nicole L Pratt; Elizabeth E Roughead; Emmae Ramsay; Amy Salter; Philip Ryan
Journal:  Drugs Aging       Date:  2010-11-01       Impact factor: 3.923

Review 3.  Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies.

Authors:  Gianluca Trifiró; Janet Sultana; Edoardo Spina
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

4.  Measuring the Effectiveness of Safety Warnings on the Risk of Stroke in Older Antipsychotic Users: A Nationwide Cohort Study in Two Large Electronic Medical Records Databases in the United Kingdom and Italy.

Authors:  Janet Sultana; Andrea Fontana; Francesco Giorgianni; Silvia Tillati; Claudio Cricelli; Alessandro Pasqua; Elisabetta Patorno; Clive Ballard; Miriam Sturkenboom; Gianluca Trifirò
Journal:  Drug Saf       Date:  2019-12       Impact factor: 5.606

Review 5.  Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review.

Authors:  Emilio Sacchetti; Cesare Turrina; Paolo Valsecchi
Journal:  Drug Saf       Date:  2010-04-01       Impact factor: 5.606

6.  Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a self-controlled case-series analysis in an Australian health care claims database.

Authors:  Nicole Pratt; Elizabeth E Roughead; Emmae Ramsay; Amy Salter; Philip Ryan
Journal:  Drug Saf       Date:  2011-07-01       Impact factor: 5.606

7.  The effects of melatonin versus placebo on delirium in hip fracture patients: study protocol of a randomised, placebo-controlled, double blind trial.

Authors:  Annemarieke de Jonghe; Barbara C van Munster; Hannah E van Oosten; J Carel Goslings; Peter Kloen; Carolien van Rees; Reinder Wolvius; Romuald van Velde; Marcel M Levi; Joke C Korevaar; Sophia E de Rooij
Journal:  BMC Geriatr       Date:  2011-07-05       Impact factor: 3.921

8.  The explanatory role of stroke as a mediator of the mortality risk difference between older adults who initiate first- versus second-generation antipsychotic drugs.

Authors:  John W Jackson; Tyler J VanderWeele; Anand Viswanathan; Deborah Blacker; Sebastian Schneeweiss
Journal:  Am J Epidemiol       Date:  2014-09-18       Impact factor: 4.897

9.  Antipsychotic use in dementia patients in a general practice setting: a Dutch population-based study.

Authors:  J Sultana; I Leal; M de Ridder; M Sturkenboom; G Trifiró
Journal:  Epidemiol Psychiatr Sci       Date:  2016-03-18       Impact factor: 6.892

Review 10.  Packages of care for dementia in low- and middle-income countries.

Authors:  Martin J Prince; Daisy Acosta; Erico Castro-Costa; Jim Jackson; K S Shaji
Journal:  PLoS Med       Date:  2009-11-03       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.